-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Duocarmazine in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Duocarmazine in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Duocarmazine in Epithelial Ovarian Cancer Drug Details: Trastuzumab duocarmazine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Duocarmazine in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Duocarmazine in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Duocarmazine in Endometrial Cancer Drug Details: Trastuzumab duocarmazine (SYD-985) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Duocarmazine in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Duocarmazine in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Duocarmazine in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Duocarmazine in Ovarian Cancer Drug Details: Trastuzumab duocarmazine (SYD-985) is under development for the...
-
Thematic Analysis
Space Economy – Thematic Intelligence
Space Economy Report Overview Space is no longer the sole domain of governments and incumbent aerospace and defense companies. Technological advances in manufacturing, propulsion, and the launch of rockets have made it much easier and less expensive to venture into space. Those businesses that pursued emerging opportunities have gained a first-mover advantage. For instance, SpaceX was the first private company to launch a spacecraft into orbit and return it safely to Earth-. The Space Economy thematic report provides an overview...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – trastuzumab duocarmazine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry trastuzumab duocarmazine Drug Details Trastuzumab duocarmazine (SYD-985) is under development for the treatment of...
-
Analyst Opinions
Internet from Sky: Can LEO Satellites Transform the Future of Connectivity?
The latest space race aims to provide satellite internet with real-time latency for data-intensive industrial and business-oriented communication applications. A shorter trip is a faster trip, hence LEO satellites positioned nearer to the earth are at an advantage to maximize data transmission. LEOs are secure as communication happens in space and hence are not likely to be influenced by natural catastrophes or man-made disasters. With terrestrial access to broadband increasingly constrained, LEOs potentially raise the bar to provide lightning speed...